A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Immunophenotyping of Orthotopic Homograft (Syngeneic) of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

12.1K views

⸱

DOI:

10.3791/57460

⸱

October 9th, 2018

 ,  ,  ,  ,  ,  ,  , 

* These authors contributed equally

In This Article

Summary

The experimental procedure on the immunophenotyping of murine orthotopic PDAC homografts aims at profiling the tumor immuno-microenvironment. Tumors are orthotopically implanted via surgery. Tumors of 200–600 mm3 in size were harvested and dissociated to prepare single-cell suspensions, followed by multi-immune marker FACS analysis using different fluorescently-labeled antibodies.

Abstract

Homograft (syngeneic) tumors are the workhorse of today's immuno-oncology (I/O) preclinical research. The tumor microenvironment (TME), particularly its immune-components, is vital to the prognosis and prediction of treatment outcomes, especially those of immunotherapy. TME immune-components are composed of different subsets of tumor-infiltrating immune cells assessable by multi-color FACS. Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest malignances lacking good treatment options, thus an urgent and unmet medical need. One important reason for its non-responsiveness to various therapies (chemo-, targeted, I/O) has been its abundant TME, consisting of fibroblasts and leukocytes that protect tumor cells from these therapies. Orthotopically implanted PDAC is believed to more accurately recapture the TME of human pancreatic cancers than conventional subcutaneous (SC) models.

Homograft tumors (KPC) are transplants of mouse spontaneous PDAC originating from genetically engineered KPC-mice (KrasG12D/+/P53-/-/Pdx1-Cre) (KPC-GEMM). The primary tumor tissue is cut into small fragments (~2 mm3) and transplanted subcutaneously (SC) to the syngeneic recipients (C57BL/6, 7–9 weeks old). The homografts were then surgically orthotopically transplanted onto the pancreas of new C57BL/6 mice, along with SC-implantation, which reached tumor volumes of 300–1,000 mm3 by 17 days. Only tumors of 400–600 mm3 were harvested per approved autopsy procedure and cleaned to remove the adjacent non-tumor tissues. They were dissociated per protocol using a tissue dissociator into single-cell suspensions, followed by staining with designated panels of fluorescently-labeled antibodies for various markers of different immune cells (lymphoid, myeloid and NK, DCs). The stained samples were analyzed using multi-color FACS to determine numbers of immune cells of different lineages, as well as their relative percentage within tumors. The immune profiles of orthotopic tumors were then compared to those of SC tumors. The preliminary data demonstrated significantly elevated infiltrating TILs/TAMs in tumors over the pancreas, and higher B-cell infiltration into orthotopic rather than SC tumors.

Introduction

Pancreatic ductal adenocarcinoma (PDAC) causes nearly half a million mortalities world-wide annually, one of the top 5 cancer killers. There are few effective treatment options and no approved immunotherapies; therefore, new treatments are desperately needed. Cancers are increasingly being recognized as immunological diseases, including PDAC, in addition to the genetic diseases as known today. Immunological and genetic factors would likely determine disease prognosis as well as treatment outcomes. Tumors evade host immune surveillance and eventually advance to cause death. Many of these immune processes occur within the tumor microenvironment (TME)1<....

Access restricted. Please log in or start a trial to view this content.

Protocol

All the protocols and amendment(s) or procedures involving the care and use of animals will be reviewed and approved by the Crown Bioscience Institutional Animal Care and Use Committee (IACUC) prior to the conduct of studies. The care and use of animals will usually be conducted in accordance with AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care) International guidelines as reported in the Guide for the Care and Use of Laboratory Animals, National Research Council (2011). All animal experimental procedures will be under sterile conditions at SPF (specific pathogen-free) facilities and conducted in strict accordance with the Guide for the ....

Access restricted. Please log in or start a trial to view this content.

Results

Orthotopic implantation of PDAC resulted in rapid tumor growth similar to that seen for SC implantation. After the donor tumor fragments were implanted into recipient mice, both subcutaneously and orthotopically according to the protocols described in Steps 2.1 and 2.2, the implanted KPC homograft tumors demonstrated similar rapid growth as shown in Figure 1A. KPC homograft tumors harvested at different time points are shown in Figure 1B<.......

Access restricted. Please log in or start a trial to view this content.

Discussion

Although studies using SC tumors are more readily conducted, orthotopically implanted tumors models can potentially be more relevant for preclinical pharmacology studies (particularly I/O investigations) to provide enhanced translatability. This report aims at helping the interested readers/audience to be able to directly visualize the technical procedures that can be used in their respective research. Our protocols demonstrate that orthotopic implantation of PDAC can result in efficient tumor growth, similar to SC impla.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

All authors are current full-time employees of Crown Bioscience, Inc.

Acknowledgements

The authors would like to thank Dr. Jody Barbeau - for critical reading and editing of the manuscript, and thank Ralph Manuel for designing artworks. The authors would also like to thank the Crown Bioscience Oncology Immuno-Oncology Biomarker team and Oncology In Vivo team, for their great technical efforts.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Anesthesia machine\SAS3119\
Trocar 20\\2 mm
Petri dish\\20 mm
100x antibiotic and antimycotic\\\
Iodophor swabs\\Daily pharmacy purchase
Alcohol swabs\\Daily pharmacy purchase
Liquid nitrogenAir chemical\\
Biosafety hoodAIRTECHBSC-1300IIA2\
FACS machine LSRFortessa X-20BDLSR Fortessa\
antibodiesBD\\
Trevigen MD or BD Matrigel Basement Membrane Matrix High concentrationBD354248\
FACS buffersBD554656Mincing buffer
Brilliant Staining BufferBD563794\
Mouse BD Fc BlockBD553142\
cell filtersBD-Falcon35235070 µm
routine blood tubeBD-Vacutainer3659742 mL
KaluzaBeckmanvs 1.5
6-well platesCorning3516\
Foxp3 Fix/Perm kitebioscience00-5523-00\
UltraComp eBeadsebioscience01-2222-42\
Centrifugeeppendorf5810R,5920R\
FlowJo softwareFlowJo LLC\vs 10.0
PBSHycloneSH30256.0150 mL
RPMI 1640HycloneSH30809.01\
Disposable, sterile scalpelsJin zhongJ1210011#
knife handleJin zhongJ11010\
eye scissors and tweezersJin zhongY00030Eye scissors 10 cm
eye scissors and tweezersJin zhongJD1060Eye tweezers 10 cm with teeth
Portable liquid nitrogen tankJinfengYDS-175-216\
Electronic balanceMetter ToledoAL2040-100 g
Miltenyi C-tubesMiltenyi130-096-334\
Miltenyi Gentle MACS with heater blocksMiltenyi120-018-306\
Tumor Dissociation KitMiltenyi130-096-730\
Cell counterNexcelomCellometerCellometer Auto T4
cryopreservation tubeNunc3754181.8 mL
Cultrex High Protein Concentration (HC20+) BMEPathClear3442-005-01\
syringesShanghai MIWA medical industry\1-5 mL
Studylog softwareStudylog\software
Studylog-Balance and supporting USBOHAUSSE601FBalance and supporting USB
Studylog-Data line of vernier calipersSylvac926.6721Data line of vernier calipers
CaliperSylvac910.1502.10Sylvac S-Cal pro
Sterilized centrifuge tubesThermo33965350 mL
Sterilized centrifuge tubesThermo33965115 mL
Ice bucketThermoKLCS-2884 °C
Ice bucketThermoPLF-276-20 °C
Ice bucketThermoDW-862626-80 °C
RNAlaterThermoam7021\

References

  1. Chevrier, S., et al. An Immune Atlas of Clear Cell Renal Cell Carcinoma. Cell. 169 (4), 736-749 (2017).
  2. Wargo, J. A., Reddy, S. M., Reuben, A., Sharma, P. Monitoring immune responses in the tumor microenvironment. Curr. Opin. Immunol. 41, 23-31 (2016).
  3. Mosely, S.....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Murine ModelsTumor MicroenvironmentTumor Infiltrating Immune CellsMulti-color FACSCell DissociationFluorescent Antibodies